PFS in grade 1 vs grade 2 (Ki-67<10%) NET
0
10
20
30
40
50
60
70
80
90
100
Time, months
Lanreotide
Autogel
120 mg
19 events
/
69 patients
median,
not
reached
Placebo
40 events / 72 patients
median, 18.3 months [95% CI: 12.7, 24.0]
Lanreotide Autogel
vs
placebo
P
=
.0016
HR = 0.43 [95% CI: 0.25, 0.74]
0
10
20
30
40
50
60
70
80
90
100
Time, months
Lanreotide
Autogel
120 mg
13 events
/
32 patients
median,
not
reached
Placebo
19 events / 29 patients
median, 12.1 months [95% CI: 9.0, 18.0]
Lanreotide
Autogel
vs placebo
P
=
.0235
HR = 0.45 [95% CI: 0.22, 0.91]
P
value derived from log-rank test; HR derived from Cox proportional hazards model
3 6 9 12
18
24 27
0
0 3 6 9 12
18
24 27
Grade 1 tumors (n= 141)
Grade 2 tumors (n= 61)
Patients Alive and With No Progression, %
CLARINET: LANREOTIDE PROLONG PFS IN
ENTEROPANCREATIC NET
Caplin ME, et al.
N Engl J Med.
2014
